Mounjaro (Tirzepatide)
60 articles on Mounjaro (Tirzepatide), researched and written by the Shotlee Editorial Team from primary sources.
I Lost 5 Stone on Mounjaro — But Now I’ve Had Enough
Natalie Lavergne transformed her health and lost 5 stone using Mounjaro, but now plans to switch to the Wegovy pill. Discover the medical realities of stopping weight loss medication.
8 min read
Study Links Hormonal Birth Control Use to Higher Likelihood of Needing Weight Loss Injections
A recent Danish study suggests that women who have used hormonal birth control may be more likely to seek weight loss injections such as Wegovy and Ozempic. This research sheds light on a long-reported, yet often unproven, connection between contraceptives and weight changes.
7 min read
Eli Lilly Prepares FDA Run for ‘Triple-G’ Weight Loss Drug With Phase 3 Data
Eli Lilly has announced positive Phase 3 results for retatrutide, positioning the triple-agonist drug for an FDA filing in 2027 with substantial weight loss outcomes.
7 min read
Meghan McCain Responds to 'Old and Ugly' Comments by Rejecting Ozempic
Meghan McCain has publicly pushed back against harsh online comments about her appearance, emphasizing her commitment to natural aging and rejecting the use of weight-loss medications like Ozempic.
6 min read
The Most Confronting Side Effect of Wegovy Weight Loss Wasn't Physical
While physical side effects of Wegovy are well-documented, one patient's experience highlights a profound, non-physical challenge: the shift in how society perceives and treats individuals after significant weight loss.
7 min read
Rosie O'Donnell: Mounjaro Changed My Life After Losing 30kg
Talk show host Rosie O'Donnell discusses her 30kg weight loss using Mounjaro, the subsequent skin concerns, and the mental health benefits of GLP-1 therapy.
6 min read
Rosie O'Donnell: Mounjaro Changed My Life After Losing 30kg
Talk show host Rosie O'Donnell shares her candid experience with Mounjaro, detailing her 30kg weight loss, Type 2 diabetes management, and the physical consequences of rapid fat loss.
12 min read
Jim Cramer on Eli Lilly Amid Rival's GLP-1 Lawsuit
Jim Cramer weighs in on Eli Lilly's position in the GLP-1 market following a lawsuit from competitor Novo Nordisk, analyzing the situation for investors.
7 min read
Mounjaro KwikPen: Your Guide to Effective Weekly Injections
This comprehensive guide explains how to use the Mounjaro KwikPen for effective weekly self-injections, detailing preparation, injection sites, and a step-by-step process to ensure proper administration and maximize treatment benefits.
7 min read
Dr. Reddy's Generic Ozempic Supplies Delayed on API Issue
Dr. Reddy's Laboratories has paused commercial production of generic semaglutide following quality concerns with the active ingredient. Here is what patients need to know about the delay and what it means for access to GLP-1 therapy.
8 min read
Semaglutide (Ozempic, Wegovy) Offers Heart Protection Beyond Weight Loss
A groundbreaking study published in The Lancet demonstrates that semaglutide, the active ingredient in Ozempic and Wegovy, provides substantial cardiovascular protection independent of the amount of weight lost. This finding reshapes our understanding of how these GLP-1 receptor agonists benefit heart health.
7 min read
Ozempic, Wegovy, and Mounjaro May Alter Taste: How Food Flavor Changes Can Impact Cravings
Discover how incretin-based therapies like Ozempic, Wegovy, and Mounjaro might be changing the way you experience food. This article delves into new research linking altered taste perception to reduced appetite and cravings, offering insights for patients and clinicians.
8 min read
Most People Who Stop GLP-1 Drugs Like Ozempic Eventually Restart Treatment
A recent study presented at ENDO 2026 sheds light on the patterns of GLP-1 medication use for type 2 diabetes, revealing that while many patients stop treatment, a substantial number later restart, suggesting a more cyclical rather than permanent discontinuation.
7 min read
Semaglutide Supply Chain Halted: What Dr. Reddy's API Issue Means for You
Dr. Reddy's Laboratories has paused semaglutide shipments due to active ingredient quality concerns. Here is a deep dive into the impact on the GLP-1 market and patient care.
7 min read
Ozempic, Wegovy, Mounjaro: How Long Do GLP-1s Stay in Your System?
Curious about how long Ozempic, Wegovy, Mounjaro, or other GLP-1 medications stay in your system after your last dose? This comprehensive guide explores the science behind their elimination and what factors influence their duration.
7 min read
Medicare's GLP-1 Weight Loss Drug Bridge: What You Need to Know
For the first time, Medicare is expanding access to GLP-1 medications for weight loss through a new pilot program. Starting July 1, eligible beneficiaries can access popular drugs like Wegovy and Zepbound for a $50 monthly copay. This groundbreaking initiative aims to make these life-changing treatments more accessible, but understanding the specifics is crucial.
7 min read
Wegovy & Mounjaro: Navigating Medicare's New Path to Weight Loss
For years, Medicare's stance on GLP-1 medications for weight loss was a firm 'no.' However, a significant shift is underway. Discover how the new 'Bridge' program opens doors to crucial weight management tools like Wegovy and Mounjaro, and what you need to know.
6 min read
Mounjaro Access Expands: Northern Ireland Launches New Weight Loss Service
Northern Ireland is set to launch a £5 million Regional Obesity Management Service, improving access to Mounjaro and lifestyle support for adults struggling with obesity.
8 min read
Beyond the Hype: Why Some Aren't Responding to GLP-1 Weight Loss Drugs
While GLP-1 agonists have revolutionized weight loss for many, a significant portion of individuals don't experience the same dramatic results. This article delves into the reasons behind GLP-1 non-response and offers guidance for those seeking effective weight management solutions.
7 min read
Ozempic, Wegovy & Mounjaro: How GLP-1s Are Reshaping the Diet Industry
The landscape of weight loss and diet trends is undergoing a seismic shift, largely driven by the widespread adoption of GLP-1 receptor agonists. From Ozempic to Wegovy and Mounjaro, these medications are not just changing how individuals manage their weight but are fundamentally altering the food industry and the very concept of dieting.
7 min read
Beyond the Hype: Understanding the 'Natural Ozempic' Gelatin Trend
A viral trend promoting a 'natural Ozempic' drink made with gelatin and water is sweeping social media. But does it live up to the hype? We explore the science behind this appetite suppressant and what health experts say about its effectiveness and safety.
6 min read
Beyond Weight Loss: GLP-1 Drugs and Unexpected Changes to Taste and Smell
The revolutionary GLP-1 medications, celebrated for their efficacy in diabetes and weight management, are now being scrutinized for a less-discussed side effect: alterations in our senses of smell and taste. A recent study suggests a tangible link between these peptide therapies and sensory disturbances.
6 min read
Beyond the Headlines: Unpacking the Real GLP-1 Weight Loss Race
The booming GLP-1 market for weight loss is often simplified by headline prescription numbers. This article delves deeper, examining the complex factors influencing the success of drugs like Wegovy, Zepbound, and Mounjaro, and what they mean for patients and the industry.
8 min read
Semaglutide Linked to Stronger Bones in Type 2 Diabetes Patients
A landmark study suggests semaglutide may protect bone strength while aiding weight loss, offering new hope for diabetes management and bone health.
8 min read
Beyond the Headlines: New GLP-1 Side Effects Uncovered on Reddit?
A groundbreaking study utilized AI to sift through over 400,000 Reddit posts, uncovering potential new side effects associated with popular GLP-1 medications such as Ozempic, Wegovy, and Mounjaro. This research highlights the growing role of real-world data in understanding medication safety.
8 min read
Beyond BMI: Hidden Health Reasons Doctors May Decline Mounjaro or Wegovy
While BMI is a primary factor, a range of underlying health conditions and personal histories can lead to a doctor declining a prescription for popular weight loss medications like Mounjaro and Wegovy. Understanding these criteria is vital before seeking treatment.
7 min read
Beyond Weight Loss: Do GLP-1 Drugs Impact Mental Health?
New research is exploring the surprising potential of GLP-1 receptor agonists, known for their role in diabetes and weight management, to also influence mental well-being. This article delves into the latest findings and what they mean for patients.
7 min read
Illicit Weight Loss Drug Ring Dismantled: 12,000 Doses Seized
A major bust at a country estate near Northampton has led to the seizure of 12,000 doses of illicit weight loss medications, including potent peptide drugs. Two men have been arrested as the Medicines and Healthcare products Regulatory Agency (MHRA) cracks down on dangerous counterfeit and unlicensed medicines.
6 min read
Beyond BMI: Why Mounjaro Eligibility is More Complex Than You Think
Many assume BMI is the sole determinant for Mounjaro prescriptions, but the reality is far more nuanced. This article explores the comprehensive health criteria healthcare providers use to ensure safe and effective treatment.
6 min read
Beyond the 'Bridal Glow': The Real Story of Mounjaro & Weight Loss
As 'Mounjaro brides' become a trend, an endocrinologist unpacks the medical realities, risks, and ethical concerns surrounding using powerful weight-loss medications for cosmetic pre-wedding transformations.
9 min read
Ozempic Price Cut: Generic Semaglutide Arrives in Canadian Pharmacies
Two generic versions of Ozempic have arrived in Canadian pharmacies, offering diabetes and weight loss patients significant cost savings compared to the brand-name medication.
7 min read
Driving on Ozempic & Mounjaro: Avoiding the £1,000 DVLA Fine
New regulations warn that GLP-1 medication users could face significant fines if side effects impair driving. Here is the complete guide to staying safe and compliant.
8 min read
Retatrutide Trials: Why Extreme Weight Loss Isn't Always Safe
Clinical trials for the triple-agonist Retatrutide show promising weight loss, but 11% of high-dose participants dropped out due to side effects.
7 min read
GLP-1 Drugs and Vision Loss: Understanding NAION Lawsuits
Recent lawsuits are raising serious questions about the potential for GLP-1 medications, widely used for diabetes and weight loss, to cause a rare but devastating eye condition known as NAION, leading to permanent vision loss. This article delves into the allegations, scientific evidence, and ongoing legal proceedings.
6 min read
Supreme Court Ruling: Medicare Drug Price Negotiations Move Forward
In a significant victory for healthcare cost containment, the Supreme Court has allowed Medicare to proceed with negotiating drug prices. This decision upholds a key provision of the Inflation Reduction Act and could impact the cost of many prescription medications, including widely used GLP-1 agonists.
6 min read
Amazon Stocks Oral Ozempic Pills: Same-Day Delivery & Pricing Guide
Amazon Pharmacy is expanding access to oral GLP-1 medications like Ozempic and Wegovy through kiosks and same-day delivery. Here is everything you need to know about pricing, logistics, and managing your treatment.
7 min read
Greg Davies Ozempic Weight Loss: Key Lessons for GLP-1 Users
Comedian Greg Davies reveals the physical and psychological effects of stopping Ozempic after significant weight loss, offering insights for patients on peptide therapy.
6 min read
GLP-1 Costs and Rising Spend: Why Primary Care is the New Cost Strategy
With healthcare costs projected to jump another 9% next year, driven significantly by GLP-1 medications like semaglutide and tirzepatide, employers face unprecedented budget pressure. This article explores why reactive cost-cutting fails and how investing upstream in robust primary care coordination is the key to sustainable financial health and better patient outcomes.
6 min read
GLP-1 Drugs & Kris Jenner: Why Some Find Them Difficult
Kris Jenner recently shared her experience with GLP-1 medications, revealing they made her feel unwell. This opens the door to understanding the nuances of these popular drugs and exploring alternative peptide therapies for weight management and overall health.
7 min read
GLP-1 Weight Loss Drugs: Why Eating Habits Matter for Success
New research suggests that the way you eat—whether driven by emotions or external cues—can significantly influence how well GLP-1 medications like Ozempic, Wegovy, and Mounjaro work for weight loss and type 2 diabetes management. Learn what this means for your treatment.
7 min read
Eli Lilly's $4.5 Billion Expansion: Fueling the Future of Weight Loss & Health
Eli Lilly's monumental $4.5 billion investment in its Indiana facilities signals a significant ramp-up in production for groundbreaking GLP-1 agonists like Mounjaro and Zepbound, alongside future weight loss and cardiometabolic disease treatments. This expansion is poised to meet surging global demand and solidify Lilly's position at the forefront of pharmaceutical innovation.
6 min read
GLP-1 Medications: Understanding Drug Interactions and Safety
GLP-1 receptor agonists are powerful tools for managing diabetes and obesity, but understanding their potential interactions with other medications is crucial for patient safety and treatment efficacy.
7 min read
Sustaining Weight Loss: Beyond Ozempic, Mounjaro & GLP-1 Therapies
Successfully losing weight with medications like Ozempic and Mounjaro is a significant achievement. However, the journey doesn't end there. This article explores how to maintain your progress and prevent weight regain after discontinuing these powerful GLP-1 receptor agonists.
8 min read
GLP-1 Agonists: Age Limits & Serious Risks of Weight Loss Drugs
This comprehensive guide delves into the critical considerations surrounding GLP-1 agonists for weight loss, addressing common concerns about age limits, potential risks, and practical advice for patients.
7 min read
GLP-1 Drugs: Ashley Graham's Concerns on Weight Loss Trends
Plus-size model Ashley Graham expresses her disappointment and concern over the increasing popularity of GLP-1 weight loss drugs, viewing it as a setback for body acceptance movements.
6 min read
GLP-1s and Pregnancy: New Study Offers Cautious Reassurance
New research from the University of St Andrews offers a glimmer of hope for individuals using GLP-1 medications who become pregnant. This comprehensive review of nearly 50,000 pregnancies suggests a potentially lower risk of adverse outcomes than previously feared, though experts emphasize caution.
7 min read
Eli Lilly's Q1 Surge: GLP-1 Success Fuels Strong Outlook
Eli Lilly's first quarter of 2026 saw record-breaking performance, largely propelled by the immense demand for its GLP-1 based therapies, Mounjaro and Zepbound. The pharmaceutical giant not only surpassed financial expectations but also significantly raised its full-year outlook, signaling continued growth and innovation in the metabolic disease space.
7 min read
Your Gut's Natural Weight Loss System: The Science Behind GLP-1 Hormones
Discover the fascinating connection between your gut microbiome, the food you eat, and the natural hormones that regulate appetite and metabolism. Learn how these internal systems are similar to groundbreaking weight loss medications like Ozempic, Wegovy, and Mounjaro.
7 min read
Mounjaro (Tirzepatide) PBS Listing Fails: Impact on Australian Patients
Eli Lilly Australia has announced that Mounjaro (tirzepatide) will not be listed on the Pharmaceutical Benefits Scheme (PBS) for Type 2 Diabetes, citing unsustainable funding conditions. This decision highlights ongoing challenges in accessing modern GLP-1 and GIP therapies.
6 min read
Understanding the Mounjaro (Tirzepatide) PBS Standoff and What It Means for Patients
Eli Lilly has declined to list its highly effective GLP-1/GIP agonist, Mounjaro (tirzepatide), on the Pharmaceutical Benefits Scheme (PBS) in Australia, citing disagreements over pricing. This decision has significant implications for patients seeking access to this crucial medication for type 2 diabetes and increasingly, for weight management.
6 min read
FDA Considers Compounding Access for Unproven Peptides: What Patients Need to Know
The FDA is evaluating the regulation of specific peptides amid growing demand. We break down the science, the risks, and the clinical implications.
2 min read
Aston Gynaecologist Investigates Ozempic, Mounjaro Impact on PCOS
A leading gynaecologist at Aston Medical School is probing whether GLP-1 drugs like Ozempic and Mounjaro could transform care for women with PCOS. With a £60,000 NHS grant, Dr Shagaf Bakour aims to evaluate their effects on metabolic health and fertility. This investigation highlights hope for better treatment pathways amid rising interest in these weight loss jabs.
5 min read
Christina Aguilera 'Thinner Than Ever' in Braless Dress Amid Ozempic Rumors
Christina Aguilera turned heads at the Breakthrough Prize Ceremony, appearing 'thinner than ever' in a plunging black leather dress that highlighted her minuscule waist. Amid ongoing Ozempic rumors, fans commented 'Ozempic strikes again' on her super-slim frame. This sighting reignites discussions on celebrity weight loss and GLP-1 medications.
5 min read
Aston University Investigates Weight-Loss Drugs for PCOS Treatment
A gynaecologist at Aston University has won a £60,000 NHS research grant to probe the potential of weight-loss drugs like Ozempic and Mounjaro in treating polycystic ovary syndrome (PCOS). This initiative aims to evaluate their impact on metabolic health and fertility in affected women. Discover the project's details and why it matters for patient care.
6 min read
Lost 9 Stone on Mounjaro: Loose Skin Sparks ElastiK Skin Business
Marc McKee dropped nine stone with Mounjaro, transforming his health but leaving him with loose skin that inspired a new business. ElastiK Skin targets GLP-1 weight loss side effects using peptides, hyaluronic acid, and LED therapy. Early users report better hydration and elasticity with consistent use.
5 min read
India Seizes 260+ Suspected Fake Mounjaro Pens, Raw Materials from Alibaba
Authorities in India have seized more than 260 suspected fake Mounjaro pens, uncovering a counterfeit operation sourcing peptides from Alibaba and selling them cheaply on IndiaMART. The primary accused lacked a pharmaceutical license and produced them at a private property. This incident underscores growing risks in the booming obesity drug market as Mounjaro becomes India's top-seller.
5 min read
Adele's Before & After Pics Highlight 100-Pound Weight Loss
Musician Adele transformed her body in 2020, losing 100 pounds via exercise and a healthy diet amid rising anxiety after her 2019 divorce. Before Ozempic and Mounjaro gained popularity, she focused on building physical and mental strength. Her before-and-after photos and candid interviews reveal a powerful story of self-improvement.
5 min read
Inside India's GLP-1 Rush: Generics, Hype, Risks
In India, the GLP-1 rush is on—patients demand Ozempic or Mounjaro by name, generics slash costs to ₹1,290/month, fueled by Instagram and forums. But endocrinologists caution against indiscriminate use amid nausea, rebound weight, and serious risks. Inside the hype reshaping obesity treatment.
5 min read
Health Canada Warns Against Buying Peptides Online—CBC News Buys Them Easily
Health Canada recently warned Canadians not to buy or use unauthorized injectable peptide drugs amid reports of adverse reactions. Yet CBC News effortlessly purchased three such products online from different sellers. Experts highlight serious risks and contrast them with regulated GLP-1 medications like Ozempic and Wegovy.
5 min read
Why Mounjaro is Having a Moment: Content Creator's Weight Loss Story
Content creator Aishwarya Mohanraj's candid video about dropping from 74kg to 52kg in six months on Mounjaro has spotlighted the injectable drug. Amid PCOS and hypothyroidism challenges, her story shifts focus from Ozempic hype. But experts warn: pair it with lifestyle changes or risk weight regain.
5 min read